South Korea
· Delayed Price · Currency is KRW PCL, Inc. Company Description
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services.
The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24.
In addition, the company offers platform services, such as SG ID for identifying novel target substances.
Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits.
PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2008 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 31 |
| CEO | Soyeon Kim |
Contact Details
Address: Star Valley, 99 Seoul, 08510 South Korea | |
| Phone | 82 2 2144 3901 |
| Website | pclchip.com |
Stock Details
| Ticker Symbol | 241820 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Soyeon Kim | Chief Executive Officer |